Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma - Top-Institutions - MDSpire

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma

  • By

  • Huiru Guo

  • Lingshuang Liu

  • Veronika Lindberg

  • Yingjun Xue

  • Jan P. A. Baak

  • July 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Longhua University Hospital
    Longhua University Hospital

    Shanghai, China

    Key Differentiators

    • Oncology

  • #2

    GARNET trial
    GARNET trial

    N/A, N/A

    Key Differentiators

    • Oncology

  • #3

    10 institutions in the United States and Europe
    10 institutions in the United States and Europe

    N/A, N/A

    Key Differentiators

    • Oncology

  • #4

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #5

    Guangdong Lung Cancer Institute
    Guangdong Lung Cancer Institute

    Guangdong, China

    Key Differentiators

    • Oncology

Original Source(s)

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR–TKI benefit in stage IV lung adenocarcinoma

  • by Huiru Guo, Lingshuang Liu, Veronika Lindberg, Yingjun Xue, Jan P. A. Baak

  • July 10, 2026

Related Content

Diagnostic performance of a single breath-hold lung MRI scan with AI-powered compressed sensing for nodule detection in comparison to photon counting detector-CT

Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review

Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review